Patents by Inventor Catalin Nistor
Catalin Nistor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230372436Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: April 26, 2023Publication date: November 23, 2023Applicant: CAMURUS ABInventors: Catalin NISTOR, Markus JOHNSSON, Fredrik TIBERG
-
Publication number: 20230285502Abstract: The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt %. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.Type: ApplicationFiled: January 30, 2023Publication date: September 14, 2023Applicant: CAMURUS ABInventors: Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Patent number: 11672843Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: GrantFiled: May 24, 2013Date of Patent: June 13, 2023Assignee: CAMURUS ABInventors: Catalin Nistor, Markus Johnsson, Fredrik Tiberg
-
Patent number: 11564968Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.Type: GrantFiled: October 1, 2021Date of Patent: January 31, 2023Assignee: CAMURUS ABInventors: Justas Barauskas, Catalin Nistor, Markus Johnsson
-
Publication number: 20220387445Abstract: The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di- or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.Type: ApplicationFiled: June 9, 2022Publication date: December 8, 2022Applicant: CAMURUS ABInventors: Fredrik TIBERG, Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Patent number: 11433120Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: GrantFiled: May 25, 2012Date of Patent: September 6, 2022Assignee: CAMURUS ABInventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
-
Publication number: 20220257694Abstract: The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt %. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.Type: ApplicationFiled: January 27, 2022Publication date: August 18, 2022Applicant: CAMURUS ABInventors: Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Publication number: 20220202898Abstract: The disclosure provides a glass syringe or a glass cartridge, containing a lipid-based pre-formulation suitable for refrigerated storage.Type: ApplicationFiled: May 29, 2020Publication date: June 30, 2022Inventors: Fredrik TIBERG, Catalin NISTOR, Markus JOHNSSON, David HEMMERLIN, Johannes KLUGE, Priyanga WICKRAMANAYAKE
-
Patent number: 11369617Abstract: The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.Type: GrantFiled: September 15, 2017Date of Patent: June 28, 2022Assignee: CAMURUS ABInventors: Fredrik Tiberg, Justas Barauskas, Catalin Nistor, Markus Johnsson
-
Publication number: 20220168381Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.Type: ApplicationFiled: October 1, 2021Publication date: June 2, 2022Applicant: CAMURUS ABInventors: Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Patent number: 11241476Abstract: The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt %. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.Type: GrantFiled: September 26, 2017Date of Patent: February 8, 2022Assignee: CAMURUS ABInventors: Justas Barauskas, Catalin Nistor, Markus Johnsson
-
Publication number: 20210308226Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: June 17, 2021Publication date: October 7, 2021Applicant: CAMURUS ABInventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
-
Patent number: 11135264Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.Type: GrantFiled: June 22, 2020Date of Patent: October 5, 2021Assignee: CAMURUS ABInventors: Justas Barauskas, Catalin Nistor, Markus Johnsson
-
Publication number: 20210268112Abstract: A composition for the delayed delivery of a peptide active agent comprising; i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle, wherein the at least one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion.Type: ApplicationFiled: March 11, 2021Publication date: September 2, 2021Applicant: CAMURUS ABInventors: Markus JOHNSSON, Fredrik JOABSSON, Catalin NISTOR, Krister THURESSON, Fredrik TIBERG
-
Publication number: 20210008151Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.Type: ApplicationFiled: June 22, 2020Publication date: January 14, 2021Applicant: CAMURUS ABInventors: Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Patent number: 10688148Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.Type: GrantFiled: March 22, 2019Date of Patent: June 23, 2020Assignee: CAMURUS ABInventors: Justas Barauskas, Catalin Nistor, Markus Johnsson
-
Publication number: 20200138954Abstract: The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt %. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.Type: ApplicationFiled: September 26, 2017Publication date: May 7, 2020Inventors: Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Publication number: 20190350841Abstract: The present invention provides a formulation comprising a lipid matrix; at least one thiolated antioxidant; at least one bioactive agent; and optionally at least one chelating agent. The bioactive agent may be a gonadotrophin-releasing hormone (GnRH) agonist; a gonadotrophin-releasing hormone (GnRH) antagonist; a luthenizing hormone releasing hormone (LHRH); and/or a luthenizing hormone releasing hormone (LHRH) related peptide.Type: ApplicationFiled: November 16, 2018Publication date: November 21, 2019Applicant: CAMURUS ABInventors: Catalin NISTOR, Fredrik TIBERG, Krister THURESSON, Markus JOHNSSON
-
Publication number: 20190262419Abstract: The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.Type: ApplicationFiled: March 22, 2019Publication date: August 29, 2019Applicant: CAMURUS ABInventors: Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON
-
Publication number: 20190255068Abstract: The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.Type: ApplicationFiled: September 15, 2017Publication date: August 22, 2019Applicant: CAMURUS ABInventors: Fredrik TIBERG, Justas BARAUSKAS, Catalin NISTOR, Markus JOHNSSON